Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Sanofi puts AI ‘Plai’ app at the center of drug discovery and clinical trial operations

By Brian Buntz | July 24, 2023

Lyon France, 3 October 2017: White logo of the french multinational pharmaceutical company Sanofi on their glass office building in Lyon France

[Keitma/Adobe Stock]

The French pharmaceutical giant Sanofi has unveiled a new AI-powered app called Plai, developed in partnership with AI platform Aily Labs. This move is part of Sanofi’s plan to become the pioneer in fully integrating AI into all operations, according to CEO Paul Hudson.

Plai, designed to compile and process Sanofi’s internal data from various departments, creates bespoke “what if” scenarios to guide decision-making. Sanofi aims to exploit Plai’s analytical capabilities to enhance strategic planning.

From ChatGPT and Google Maps to Plai

Sanofi’s AI aspirations are longstanding. In 2022, the company launched its inaugural digital accelerator, supporting the adoption of digital, data and AI across operations. That same year, Sanofi acquired Amunix Pharmaceuticals, tapping its AI technology to develop targeted cancer therapies that spare healthy tissue. Also in 2022, the company opened an Artificial Intelligence Centre of Excellence in Toronto, adding to its international network of digital hubs in Paris, Boston, New York City and Barcelona.

Diane Wuest

Diane Wuest

One fact that has changed in the past year is public consciousness concerning AI. “For instance, AI models like ChatGPT have made AI accessible to the layperson,” said Diane Wuest, head of digital R&D at Sanofi. These days, AI-powered apps are a commonplace feature on smartphones. For instance, the public has become accustomed to using apps like Google Maps to find the best route based on live traffic analysis. “This shift towards AI integration in everyday life has influenced people’s expectations in the workplace,” Wuest said. “They wonder why they can’t have similar AI-driven tools for their professional tasks.”

The success stories from other industries have acted as catalysts, speeding the adoption of AI in the pharma industry. “At Sanofi, we’re embracing this change,” Wuest said. “The recent pandemic showed us that we can fast-track the process of bringing drugs to the market, and AI applications can further accelerate this process.”

She explains that the Plai app anchors their digital approach: “The Plai application is used across the whole company, and that’s why it’s considered ‘at scale.’ The intent of the app is to create transparency and facilitate good business discussions. It starts by visualizing data through dashboards. Then we layer on AI to inform decisions using that data. We leverage AI algorithms to generate predictions and simulations, guiding choices on various project aspects.”

AI upskilling Sanofi

Highlighting the need for digital literacy across all company levels, Wuest discussed Sanofi’s initiatives to address this. ‘Certainly, there is a learning curve when it comes to using AI technology,’ she acknowledged. To confront this challenge, the company has introduced an upskilling program, the Digital Learning Institute, which offers a wide range of both virtual and in-person courses. ‘Pharma has traditionally externalized the tech aspect, but now we’re building more internally and hiring talent with those skills,’ Wuest notes.”

Aligned with its unwavering commitment to training, Sanofi also champions Agile ways of working. Wuest stressed this focus, stating, “We understand that this process is a multi-year journey and should be treated as a career development path.” Consequently, the company provides substantial support and resources to cultivate this approach, recognizing its integral role in their digital transformation.

Powering research and drug development with AI

In R&D at Sanofi, AI has manifold uses. “At a company as large as ours, we use every type of AI,” Wuest explains. Notably, AI builds disease models and elucidates mechanisms, aiding the discovery of novel targets or indications. “Once the target is identified, we use AI every step of the way in creating the molecule,” she notes, expediting the process.

“We’re looking for novel molecules, not generics,” Wuest emphasizes after describing AI’s role in development, “we’re constantly on the cutting edge, seeking new methods from academia or startups.”

Sanofi’s data scientists work with R&D as well as in digital groups across the company. Wuest explained that the data science talent is decentralized, rather than being concentrated in one central AI hub.

Wuest emphasizes the robust internal backing for AI adoption. “Our goal is to become the first pharma company powered by AI at scale,’ she said, noting that comprehensive integration ensures the ‘AI solutions are sustainable, supported, and improved over time. Our strategy is innovation without borders,” according to Wuest, involving partnerships with academics, startups, and tech/biotech giants.”

Charting the AI future at Sanofi

The need for integration and objective assessment methods for AI systems continue to be paramount. This shift toward an AI-focused approach marks merely the first stage of a sweeping transformation.

Sanofi’s AI adoption remains nascent. The company’s swift expansion links to burgeoning AI fluency company-wide. “We’re at only the beginning. The pace at which we’re growing is incredibly fast,” says Wuest, noting this spurs unity, not division between digital and R&D. She foresees AI deeply embedded within Sanofi, its “language spoken throughout the whole company, becoming the fabric of it all.”


Filed Under: Data science, Industry 4.0, machine learning and AI
Tagged With: AI in Pharma, AI integration, digital transformation, drug development, Pharmaceutical Innovation, Plai app, Sanofi
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
FDA’s genAI push could save CDER hundreds of thousands of review hours annually
Elsevier plugs 500,000 ClinicalTrials.gov records into Embase
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE